Comparing Enliven Therapeutics (NASDAQ:ELVN) and Integrated BioPharma (OTCMKTS:INBP)

Integrated BioPharma (OTCMKTS:INBP) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation and Earnings

This table compares Integrated BioPharma and Enliven Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated BioPharma	$50.32 million	0.17	$110,000.00	$0.03	9.67
Enliven Therapeutics	N/A	N/A	-$71.58 million	($1.89)	-10.51

Integrated BioPharma has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Integrated BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Integrated BioPharma and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integrated BioPharma	1.78%	4.79%	3.54%
Enliven Therapeutics	N/A	-29.46%	-27.33%

Institutional & Insider Ownership

25.3% of Integrated BioPharma shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 67.2% of Integrated BioPharma shares are owned by company insiders. Comparatively, 29.2% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Integrated BioPharma has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Integrated BioPharma and Enliven Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated BioPharma	0	0	0	0	0.00
Enliven Therapeutics	0	0	4	1	3.20

Enliven Therapeutics has a consensus price target of $38.75, indicating a potential upside of 95.12%. Given Enliven Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than Integrated BioPharma.

Summary

Integrated BioPharma beats Enliven Therapeutics on 8 of the 14 factors compared between the two stocks.

About Integrated BioPharma

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.